<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168117">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844999</url>
  </required_header>
  <id_info>
    <org_study_id>12-363</org_study_id>
    <secondary_id>2R01NR009692-05</secondary_id>
    <nct_id>NCT01844999</nct_id>
  </id_info>
  <brief_title>Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks</brief_title>
  <official_title>Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether using the P3P website can increase
      decisional preparation and satisfaction, and decrease decisional conflict, in men deciding
      how to manage early stage prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Decisional conflict</measure>
    <time_frame>Change from baseline to 6-months</time_frame>
    <safety_issue>No</safety_issue>
    <description>O'Connor, 1995, Decisional conflict scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preparation for decision making</measure>
    <time_frame>1-month after study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Graham and O'Connor, 1995, Preparation for decision making scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with decision</measure>
    <time_frame>6-months after study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Holmes-Rovner et al, 1996, Satisfaction with decision scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance of care choice selected with self-reported influential personal preferences</measure>
    <time_frame>6-months from study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Odds ratio of selecting a care option for prostate cancer concordant with avoiding prioritized side effects (XBRT or brachytherapy if concerned with sexual function; prostatectomy if concerned with bowel function; active surveillance if concerned with sexual, bowel, and/or bladder function; any treatment if not concerned with any side effect).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net cost and benefit of the intervention</measure>
    <time_frame>1-week after study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cost to the patient will be measured in hours valued according to patient work status, income, and use of time. Benefit will be measured with Willingness to pay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment decision</measure>
    <time_frame>6-months from study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration (in days) from pre-decision baseline questionnaire until patient decides on a care option for prostate cancer, either an active treatment type or active surveillance. Measured by patient recall at 6-months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">625</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Usual patient education + standard educational websites</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual patient education + P3P decision support website</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Personal Patient Profile - Prostate (P3P)</intervention_name>
    <description>Website supporting informed patient decision making about prostate cancer care through tailored education and coaching</description>
    <arm_group_label>Usual patient education + P3P decision support website</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard prostate cancer information websites</intervention_name>
    <description>Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics</description>
    <arm_group_label>Usual patient education + standard educational websites</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven diagnosis of prostate cancer, T1 or T2 of any risk level

          -  Biopsy done at enrolling site

          -  Upcoming appointment with consulting specialist at enrolling study site

          -  Able to read, write, understand English

        Exclusion Criteria:

          -  Two or more post-biopsy specialist consults

          -  Begun treatment (or active surveillance)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna L Berry, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna L Berry, PhD, RN</last_name>
    <phone>617.632.1909</phone>
    <email>donna_berry@dfci.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Halpenny, MA</last_name>
    <phone>617.582.7124</phone>
    <email>barbara_halpenny@dfci.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 18, 2013</lastchanged_date>
  <firstreceived_date>April 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Decision</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
